Nicholas: Robust numbers - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Nicholas: Robust numbers

Jul 19, 2002

Nicholas Piramal has recorded an encouraging 20% topline growth for 1QFY03. Net profit, excluding extraordinary expenses grew by 69% YoY. The extraordinary charge of Rs 25 m was on account of amortisation of VRS and restructuring expenses. Operating margins registered a 100 basis points rise. The first quarter numbers of the current year include figures of ICI Pharma Ltd, acquired by the company recently. Hence, the results are not exactly comparable with corresponding previous quarter.

(Rs m)1QFY021QFY03% Change
Sales 1,860 2,232 20.0%
Other Income 69 189 172.8%
Expenditure 1,530 1,814 18.6%
Operating Profit (EBDIT) 330 418 26.8%
Operating Profit Margin (%)17.7%18.7% 
Interest 113 116 2.5%
Depreciation 43 65 51.8%
Profit before Tax 243 426 75.1%
Other Adjustments (27) (25) 
Tax 34 90 161.6%
Profit after Tax/(Loss) 182 312 71.2%
Net profit margin (%)9.8%14.0% 
No. of Shares (eoy) (m) 38.0 38.0  
Diluted Earnings per share 19.1 32.8  
P/E (at current price) 8 

The company's formulations business has recorded a 20% growth over previous corresponding quarter, outperforming industry growth rates. Nicholas Piramal, together with its joint ventures, continued to maintain its second rank in domestic formulations as per ORG. The company also enjoys first rank in the cardio-vascular segment (CVS), post-acquisition of the pharma business of ICI India Ltd. in March 2002. The rise in operating margins reflect restructuring plans, including reshuffling of product portfolio implemented by the company in the last financial year.

At the current market price of Rs 266, the stock is trading at 8x it annualised earnings for 1QFY03. The company’s investments and acquisition synergies are expected to start percolating into the financial numbers in the current year. Immediate cash flows from sale of property and effective utilisation of internal accruals is expected to ensure considerable savings in interest costs for Nicholas Piramal in the current year.

Equitymaster requests your view! Post a comment on "Nicholas: Robust numbers". Click here!

  

More Views on News

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)

Jun 8, 2021

Here's a rundown on the latest quarterly results of Jubilant Pharmova.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS